Abstract:Left ventricular diastolic dysfunction resulting in heart failure with preserved ejection fraction (HFpEF) can be further exacerbated by concurrent chronic conditions. In patients with HFpEF, type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD), there is a significant increase in all-cause and cardiovascular mortality. While all three conditions commonly coexist, there is limited data and very few studies investigating readmission, mortality, length of stay, and healthcare utilization when all three diseases are present. We sought to determine the effect of CKDIII/IV on the 30-day readmission rate (30-dr) for HFpEF in individuals with coexisting T2DM and its impact on healthcare utilization and economic burden. We conducted a retrospective study of patients admitted with HFpEF with coexisting T2DM between 2016 and 2020 using the Nationwide Readmissions Database. Variables were identified using their ICD-10 codes. Patients were included if they were at least 18 years of age with T2DM and admitted with a primary diagnosis of HFpEF. They were then stratified by the presence or absence of CKD III/IV during their index admission. The primary outcome was 30-dr, while secondary outcomes were length of stay (LOS), inpatient mortality, and resource utilization defined by hospital charge (HC). Multivariate linear, Cox, and logistic regression analyses were performed. Between 2016 and 2020 164,5569 patients with HFpEF and coexisting T2DM met the inclusion criteria. The mean age was 72.6 ± 11.8 years and 58% (n = 97,076) were females. Of these, 34.6% (n = 56,863) had CKD III/IV. The mean age was 74.5 ± 10.8 years in the CKD III/IV group versus 71.6 ± 12.1 in the non-CKD III/IV group (adjusted Wald test p < 0.001). Multivariate logistic regression models adjusting for other clinical variables showed higher odds for 30-dr (OR 1.07 95% CI 1.02 - 1.12, p < 0.001) in patients with CKD III/IV when compared to the non-CKD III/IV group. The mean LOS on index admission was 5.7 ± 5.1 days (CKD III/IV) versus 5.2 ± 5.1 (non-CKD III/IV). On readmission, LOS was higher in the CKD III/IV group compared to the non-CKD III/IV group (6.6 ± 5.5 days versus 5.9 ± 5.7 (adjusted Wald test, p < 0.001)). HC on index admission had a mean of $11,916.7 versus $11,256.7, compared to $13,984.8 versus $14,032.4 on readmission r in CKD III/IV versus non-CKD III/IV group, respectively (adjusted Wald test, p < 0.001). Cox regression analysis revealed no statistically significant differences in the hazard ratio for inpatient mortality between the two groups (HR 0.89 95% CI 0.78 - 1.01, p = 0.069). Patients with HFpEF and T2DM with concurrent CKD III/IV have an increased risk of readmission within 30 days and have a longer LOS and higher healthcare costs on their index admission as well as during their 30-dr. Preventing readmission in this high-risk population is necessary to promote better outcomes and reduce the economic burden on the healthcare system.

Disparities in 30-Day Readmission Between Medicare/Medicaid and Private Insurance Among Patients With Heart Failure Screened for Cognitive Impairment

Racial Disparities in Readmission Rates among Patients Discharged to Skilled Nursing Facilities

Factors associated with racial differences in all-cause 30-day readmission in adults with cardiovascular disease: an observational study of a large healthcare system

Socioeconomic and Demographic Determinants of Readmission Rates in Congestive Heart Failure Patients: Insights From the Nationwide Readmissions Database

Causes and Temporal Patterns of 30-Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction.

Social Determinants of Health and 30-Day Readmissions Among Adults Hospitalized for Heart Failure in the REGARDS Study

30-day Readmission And Economic Burden Among Patients With Chronic Diastolic Heart Failure With Coexisting Type 2 Diabetes And Chronic Kidney Disease Iii/iv

Trends in 30-Day Readmission Rates for Medicare and Non-Medicare Patients in the Era of the Affordable Care Act

Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients

In-Hospital Mortality Rate and Predictors of 30-Day Readmission in Patients With Heart Failure Exacerbation and Atrial Fibrillation: A Cross-Sectional Study

Decreasing 30-Day Readmission Rates in Patients With Heart Failure

Comparison of Length of Stay, 30-Day Mortality, and 30-Day Readmission Rates in Medicare Patients with Heart Failure and with Reduced Versus Preserved Ejection Fraction

Disparities in Obstetric Readmissions: A Multistate Analysis, 2007-2014

Identifying racial disparities in the management of heart failure with reduced ejection fraction

Association Between Socioeconomic Disadvantage and Risks of Early and Recurrent Admissions Among Patients With Newly Diagnosed Heart Failure

Effect of Discharge Readiness on 30-Day Readmissions Among Older Adults Living With Multiple Chronic Conditions

The Influence of Social Isolation and Medical Comorbidities on Geriatric Congestive Heart Failure Hospital Readmissions

Trends in 30- and 90-Day Readmission Rates for Heart Failure

Predicting Risk Factors for 30-Day Readmissions Following Discharge From Post-Acute Care

Trends and Disparities in Ambulatory Follow-Up After Cardiovascular Hospitalizations : A Retrospective Cohort Study

30-day Readmission Outcomes In Young Patients With Heart Failure From 2010 Through 2019 - National Readmission Database Analysis